Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) kicked off on Tuesday, up 1.77% from the previous trading day, before settling in for the closing price of $50.90. Over the past 52 weeks, RARE has traded in a range of $31.52-$54.56.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 63.06%. While this was happening, its average annual earnings per share was recorded 22.83%. With a float of $86.75 million, this company’s outstanding shares have now reached $92.17 million.
Let’s determine the extent of company efficiency that accounts for 1276 employees.
Ultragenyx Pharmaceutical Inc. (RARE) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ultragenyx Pharmaceutical Inc. is 5.88%, while institutional ownership is 88.95%. The most recent insider transaction that took place on Aug 06 ’24, was worth 1,003,418. Before that another transaction happened on Aug 06 ’24, when Company’s President & CEO sold 20,000 for $50.17, making the entire transaction worth $1,003,400. This insider now owns 2,243,985 shares in total.
Ultragenyx Pharmaceutical Inc. (RARE) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 22.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to -15.75% drop over the previous five years of trading.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Trading Performance Indicators
Take a look at Ultragenyx Pharmaceutical Inc.’s (RARE) current performance indicators. Last quarter, stock had a quick ratio of 3.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.29, a number that is poised to hit -1.47 in the next quarter and is forecasted to reach -5.20 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc. (RARE)
Looking closely at Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), its last 5-days average volume was 0.63 million, which is a drop from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 92.58%. Additionally, its Average True Range was 2.14.
During the past 100 days, Ultragenyx Pharmaceutical Inc.’s (RARE) raw stochastic average was set at 95.11%, which indicates a significant decrease from 97.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.40% in the past 14 days, which was higher than the 47.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.53, while its 200-day Moving Average is $43.97. However, in the short run, Ultragenyx Pharmaceutical Inc.’s stock first resistance to watch stands at $52.35. Second resistance stands at $52.89. The third major resistance level sits at $53.75. If the price goes on to break the first support level at $50.94, it is likely to go to the next support level at $50.08. Should the price break the second support level, the third support level stands at $49.54.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Key Stats
The company with the Market Capitalisation of 4.77 billion has total of 83,133K Shares Outstanding. Its annual sales at the moment are 434,250 K in contrast with the sum of -606,640 K annual income. Company’s last quarter sales were recorded 147,030 K and last quarter income was -131,600 K.
